GE9:F:F-Genmab A/S (EUR)

COMMON STOCK | |

Last Closing

USD 230.2

Change

-2.90 (-1.24)%

Market Cap

USD 15.01B

Volume

36.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-02 )

Largest Industry Peers for

Symbol Name Price(Change) Market Cap
NNND:F Tencent Holdings Ltd

+0.06 (+0.12%)

USD 430.48B
MATA:F Panasonic Corporation

+0.01 (+5.88%)

USD 20.38B
1CK:F CK Asset Holdings Limited

-0.01 (-0.39%)

USD 12.73B
0PY:F Paycom Soft

+0.60 (+0.46%)

USD 7.72B
KMBA:F SK TELECOM CO.LTD.ADR 5/9

+0.20 (+1.10%)

USD 7.37B
UIPN:F Unipol Gruppo Finanziario Spa

+0.36 (+3.89%)

USD 6.70B
2U4:F HICL Infrastructure PLC

-0.01 (-0.70%)

USD 2.68B
CLN:F The City of London Investment ..

+0.18 (+3.55%)

USD 1.94B
R7I:F RENEWABLES INFRASTRUCTURE

N/A

USD 1.74B
JR0:F Just Group plc

+0.02 (+1.64%)

USD 1.33B

ETFs Containing GE9:F

N/A

Market Performance

  Market Performance vs. Industry/Classification () Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -19.90% N/A N/A 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.90% N/A N/A 20% F
Trailing 12 Months  
Capital Gain -33.20% N/A N/A 21% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.20% N/A N/A 20% F
Trailing 5 Years  
Capital Gain 42.76% N/A N/A 68% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.76% N/A N/A 55% F
Average Annual (5 Year Horizon)  
Capital Gain 13.90% N/A N/A 80% B-
Dividend Return 13.90% N/A N/A 73% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 31.73% N/A N/A 37% F
Risk Adjusted Return 43.79% N/A N/A 68% D+
Market Capitalization 15.01B N/A N/A 90% A-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike